NBIX: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/95333c8a-dd4a-4079-ac83-cae61e8e63bf/","filing_uuid":"95333c8a-dd4a-4079-ac83-cae61e8e63bf","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/95333c8a-dd4a-4079-ac83-cae61e8e63bf/print/","filing_document_content_type":"text/html","income":null,"expenses":"940000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Aaron Cohen","dt_posted":"2026-07-20T12:39:09-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"6027 Edgewood Bend Court","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105485,"url":"https://lda.gov/api/v1/registrants/401105485/","house_registrant_id":null,"name":"NEUROCRINE BIOSCIENCES, INC","description":"Drug discovery and development","address_1":"6027 Edgewood Bend Court","address_2":null,"address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"FREDERICK DOMBO","contact_telephone":"+1 202-887-1485","dt_updated":"2026-07-30T11:04:36.757386-04:00"},"client":{"id":203759,"url":"https://lda.gov/api/v1/clients/203759/","client_id":12,"name":"NEUROCRINE BIOSCIENCES, INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-09-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services and the Department of Veterans Affairs for physical conditions associated with mental illness, such as Tardive Dyskinesia.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}